%D8%AF%D8%A7%D8%B3%D8%A7%D8%AA%D9%8A%D9%86%D9%8A%D8%A8DasatinibCategory:DasatinibDasatinibDasatinibDasatinib%D8%AF%D8%A7%D8%B3%D8%A7%D8%AA%DB%8C%D9%86%DB%8C%D8%A8DasatinibiDasatinib%E3%83%80%E3%82%B5%E3%83%81%E3%83%8B%E3%83%96Dasatinib%E0%AC%A1%E0%AC%BE%E0%AC%B8%E0%AC%BE%E0%AC%9F%E0%AC%BF%E0%AC%A8%E0%AC%BF%E0%AC%ACDasatynibDasatinibe%D0%94%D0%B0%D0%B7%D0%B0%D1%82%D0%B8%D0%BD%D0%B8%D0%B1DasatinibDasatinib%D0%94%D0%B0%D0%B7%D0%B0%D1%82%D0%B8%D0%BD%D1%96%D0%B1DasatinibQ419940%E8%BE%BE%E6%B2%99%E6%9B%BF%E5%B0%BC
about
Explore the Synergy of Combination TKI TherapyValproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid TumorKorean Early Access ProgramPhase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast CancerA Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple MyelomaGemcitabine and Dasatinib in Advanced Solid TumorsDasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaPhase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast CancerA Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast CancerTherapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib TherapyTreatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged MelanomaA Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-AlphaPhase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast CancerMultimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk NeuroblastomaDasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in JapanKorean Post-marketing Surveillance for Sprycel®Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid LeukaemiaPediatric Philadelphia Positive Acute Lymphoblastic LeukemiaPhase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerDasatinib in Treating Patients With Previously Treated Malignant MesotheliomaDasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerDasatinib in Treating Patients With Previously Treated Metastatic Colorectal CancerFOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal CancerStudy of Dasatinib and Bendamustine in Chronic Lymphocytic LeukemiaDasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeA Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid LeukemiaNeoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate CancerDasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland TumorsRuxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid LeukemiaBMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib MesylateDasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid LeukemiaBMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic LeukemiaDasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylatePembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseTreatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic LeukemiaRandomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
P4844
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasThe new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.Dasatinib: an anti-tumour agent via Src inhibition.Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dEffect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivoEffects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell linesManagement of Bcr-Abl-positive leukemias with dasatinib.Practical management of dasatinib for maximum patient benefit.Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.Dasatinib inhibits proinflammatory functions of mature human neutrophilsDasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor.Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case reportMatching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemiaDasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case reportPaclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian CancerLeveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast feverManagement of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single centerSrc kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cellsDasatinib/HP-β-CD Inclusion Complex Based Aqueous Formulation as a Promising Tool for the Treatment of Paediatric Neuromuscular DisordersRegulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway
P921
Q27906817-69B898F0-A2DE-4815-82D1-7427F0C08E17Q27906817-C0E07C85-416E-41A7-97EB-38F61D55BAF5Q29938345-C68358A3-8233-4AE5-A87A-F792CBB42213Q29938345-FA73967C-6C8D-4441-A9FE-1FDA123F677AQ29938509-CFF04C20-25F4-425B-8B42-BED5613B0017Q29938513-755F9834-DBA1-426B-BF05-88898EC78866Q29938515-4992BE7A-BD2F-45FE-8BE8-8857709581C7Q29938516-815C8EBE-C0BD-43EB-AB2F-5D144A0F5A7EQ29938523-9F2558D3-60F4-43A0-9905-570C81274A36Q29938702-662E19CA-B75F-4101-94AC-BBCDA5D64710Q29938702-81FC1053-F914-4DCB-A3B8-7CB2E4DD64DCQ29938706-B85EB8DF-20E4-4676-8196-8199E1F6A2E5Q29938707-77A2B744-B997-471E-86F0-4801782487EEQ29938714-10AB56DF-D4E1-4A3B-90DC-914B2360E754Q32965306-029804AC-3029-44DD-82E6-794BFFB5B70EQ32965310-A0F53B9F-A12B-4786-BB3C-65CA0B2D1B32Q32965324-BF3D0906-46E0-4B26-938D-BA2BBF95E75CQ32965330-ED730C5E-39AD-4CFA-BF52-231988A9B030Q38153149-4C5DC2DF-0AC5-498A-8B36-8E6BFACE2EAB
P3354
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Dasatinib
@ca
Dasatinib
@de
Dasatinib
@es
Dasatinib
@nl
Dasatinib
@sh
Dasatinib
@sr
Dasatinib
@vi
Dasatinibi
@fi
dasatinib
@en
dasatinib
@fr
type
label
Dasatinib
@ca
Dasatinib
@de
Dasatinib
@es
Dasatinib
@nl
Dasatinib
@sh
Dasatinib
@sr
Dasatinib
@vi
Dasatinibi
@fi
dasatinib
@en
dasatinib
@fr
altLabel
302962-49-8
@fr
BMS 345825
@en
BMS 354825
@en
BMS 35482513
@en
BMS-354825
@en
BMS-354825
@pt
C22H26ClN7O2S
@fr
Dasatinib
@pt
Sprycel
@de
Sprycel
@nl
prefLabel
Dasatinib
@ca
Dasatinib
@de
Dasatinib
@es
Dasatinib
@nl
Dasatinib
@sh
Dasatinib
@sr
Dasatinib
@vi
Dasatinibi
@fi
dasatinib
@en
dasatinib
@fr